MTO1

Across TCGA pan-cancer cohorts, MTO1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MTO1 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MTO1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTO1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and COAD are the cancer types where MTO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.812	0.562	.007	20	view →
LUAD	OS	Median	III,IV	0.879	0.359	.003	20	view →
COAD	DFS	Median	All	1.000	0.929	.040	12	view →
CCRCC	OS	Median	All	0.984	0.903	.026	3	view →
PDAC	OS	Median	IV	0.643	0.836	.038	3	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →
LSCC	OS	Tertile	All	1.000	0.725	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MTO1–GBM (DFS)

Open the GBM breakdown →